Eikon Therapeutics, Inc. (EIKN) Stock Price & Analysis
EIKN Stock Chart & Stats
- Day’s Range
- $5.63 - $6.07
- 52-Week Range
- $5.01 - $17.40
- Previous Close
- $5.84
- Volume
- N/A
- Average Volume (3M)
- 538.00K
- Market Cap
- $316.32M
- Enterprise Value
- $427.28M
- Total Cash (Recent Filing)
- $531.58M
- Total Debt (Recent Filing)
- $252.22M
- Price to Earnings (P/E)
- ―
- Beta
- 1.58
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Eikon Therapeutics, Inc. News
Eikon Therapeutics Advances EIK1005 Cancer Trial, Sharpening Its Precision Oncology Story
Eikon Therapeutics, Inc. ($EIKN) announced an update on their ongoing clinical study. Eikon Therapeutics, Inc. is running a multicenter Phase 1/2 study called EIK1005-002 to test its Werner helicase inhibitor
Brian Cheng Initiates Buy on Eikon Therapeutics, Citing Advancing Oncology Pipeline and Strategic PARP1/WRN Programs
J.P. Morgan analyst Brian Cheng has maintained their bullish stance on EIKN stock, giving a Buy rating yesterday. Brian Cheng has given his Buy rating due to a combination of
EIKN FAQ
What was Eikon Therapeutics, Inc.’s price range in the past 12 months?
What is Eikon Therapeutics, Inc.’s market cap?
When is Eikon Therapeutics, Inc.’s upcoming earnings report date?
How were Eikon Therapeutics, Inc.’s earnings last quarter?
Is Eikon Therapeutics, Inc. overvalued?
Does Eikon Therapeutics, Inc. pay dividends?
What is Eikon Therapeutics, Inc.’s EPS estimate?
How many shares outstanding does Eikon Therapeutics, Inc. have?
What happened to Eikon Therapeutics, Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Eikon Therapeutics, Inc.?
What is the TipRanks Smart Score and how is it calculated?
Eikon Therapeutics, Inc. Stock Smart Score
Company Description
Eikon Therapeutics, Inc.
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Roger Perlmutter
- Employees
- 384
- Website
- eikontx.com
- Address
- 230 Harriet Tubman Way, Millbrae, CA, 94030, US
Eikon Therapeutics, Inc. (EIKN) Earnings & Revenues
EIKN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 6 | 10 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 3 | 0 | 7 |











